In a recent phase I/II clinical trial, CARCIK-CD19 demonstrated robust safety and efficacy in 36 patients with B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Here, CD19 is linked to acute lymphoblastic leukemia.